Related Experiment Videos
The exciting future of antifungal therapy
1Department of Pediatrics, Rainbow Babies and Children's Hospital, University Hospitals of Cleveland, OH 44106, USA. mnn2@po.cwru.edu
Abstract:
Invasive fungal infections are becoming more common. Current therapy is generally limited to amphotericin B in its parent and lipid formulations, 5-fluctyosine, fluconazole, and itraconazole. Toxicity, drug-drug interactions, and increasing fungal resistance reduce the usefulness of these drugs, and the need for new therapies is pressing. This article briefly discusses the limitations of antifungal minimum inhibitory testing, and then summarizes new antifungal drugs in development that have been tested in humans. It also addresses novel treatment strategies such as drug combination therapy, pharmacological reformulations to improve the efficacy or reduce the toxicity of current antifungal drugs, immune function augmentation, and vaccine development. All of these strategies, although in their infancy, will enhance the clinician's ability to care for patients with invasive fungal infections.
Insights
New antifungal drugs and novel therapies are urgently needed due to rising invasive fungal infections and resistance to current treatments. Emerging strategies like combination therapy and immune augmentation show promise for improved patient care.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pharmacology
Background:
- Invasive fungal infections (IFIs) are increasing globally.
- Current antifungal therapies (amphotericin B, 5-fluconazole, fluconazole, itraconazole) face limitations including toxicity, drug interactions, and emerging fungal resistance.
- There is a pressing need for novel antifungal treatments and strategies.
Purpose of the Study:
- To review the limitations of current antifungal minimum inhibitory concentration (MIC) testing.
- To summarize new antifungal drugs currently in human trials.
- To discuss innovative treatment strategies for IFIs.
Main Methods:
- Literature review of existing antifungal therapies and their limitations.
- Summary of clinical trial data for novel antifungal agents.
- Exploration of emerging treatment modalities for invasive fungal infections.
Main Results:
- Current antifungal minimum inhibitory testing has significant limitations.
- Several new antifungal drugs are in various stages of human clinical development.
- Novel strategies including combination therapy, drug reformulation, immune augmentation, and vaccine development are under investigation.
Conclusions:
- The development of new antifungal drugs and treatment strategies is critical to combat rising IFIs and antifungal resistance.
- Emerging therapies, though in early stages, hold potential to significantly improve clinical management of patients with invasive fungal infections.
- A multi-pronged approach combining new drugs and innovative strategies is essential for future IFI treatment.